JP3144895B2 - Medical adhesive tape or sheet - Google Patents
Medical adhesive tape or sheetInfo
- Publication number
- JP3144895B2 JP3144895B2 JP17288792A JP17288792A JP3144895B2 JP 3144895 B2 JP3144895 B2 JP 3144895B2 JP 17288792 A JP17288792 A JP 17288792A JP 17288792 A JP17288792 A JP 17288792A JP 3144895 B2 JP3144895 B2 JP 3144895B2
- Authority
- JP
- Japan
- Prior art keywords
- sensitive adhesive
- pressure
- weight
- adhesive tape
- sheet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002390 adhesive tape Substances 0.000 title claims description 12
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 75
- 229920001971 elastomer Polymers 0.000 claims description 30
- -1 fatty acid ester Chemical class 0.000 claims description 28
- 239000010410 layer Substances 0.000 claims description 25
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 22
- 229920005989 resin Polymers 0.000 claims description 19
- 239000011347 resin Substances 0.000 claims description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 18
- 239000000194 fatty acid Substances 0.000 claims description 18
- 229930195729 fatty acid Natural products 0.000 claims description 18
- 230000035699 permeability Effects 0.000 claims description 17
- 229920003169 water-soluble polymer Polymers 0.000 claims description 15
- 229930195733 hydrocarbon Natural products 0.000 claims description 12
- 150000002430 hydrocarbons Chemical class 0.000 claims description 12
- 150000005846 sugar alcohols Polymers 0.000 claims description 11
- 239000004215 Carbon black (E152) Substances 0.000 claims description 9
- 229920002725 thermoplastic elastomer Polymers 0.000 claims description 7
- 229920001400 block copolymer Polymers 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 description 23
- 239000000853 adhesive Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 230000007794 irritation Effects 0.000 description 9
- 239000000123 paper Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 6
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229920001083 polybutene Polymers 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 239000012943 hotmelt Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000011076 sorbitan monostearate Nutrition 0.000 description 4
- 239000001587 sorbitan monostearate Substances 0.000 description 4
- 229940035048 sorbitan monostearate Drugs 0.000 description 4
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 4
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000013032 Hydrocarbon resin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229920006270 hydrocarbon resin Polymers 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229940049964 oleate Drugs 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 150000003097 polyterpenes Chemical class 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940093625 propylene glycol monostearate Drugs 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- DUUKZBGYNMHUHO-UHFFFAOYSA-N 253MC0P0YV Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)CO DUUKZBGYNMHUHO-UHFFFAOYSA-N 0.000 description 1
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241001566735 Archon Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920004939 Cariflex™ Polymers 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 229920006465 Styrenic thermoplastic elastomer Polymers 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- NPTLAYTZMHJJDP-KTKRTIGZSA-N [3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO NPTLAYTZMHJJDP-KTKRTIGZSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- IZJRISIINLJVBU-UHFFFAOYSA-N beta-Butoxyethyl nicotinate Chemical compound CCCCOCCOC(=O)C1=CC=CN=C1 IZJRISIINLJVBU-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010538 cationic polymerization reaction Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- ODCCQUXDUXHSBP-UHFFFAOYSA-N decanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCC(O)=O ODCCQUXDUXHSBP-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011086 glassine Substances 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000005001 laminate film Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 150000005673 monoalkenes Chemical class 0.000 description 1
- 108010050062 mutacin GS-5 Proteins 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- DGPCSURYVBYWAT-UHFFFAOYSA-N propane-1,2,3-triol;tetradecanoic acid Chemical compound OCC(O)CO.CCCCCCCCCCCCCC(O)=O DGPCSURYVBYWAT-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229950003429 sorbitan palmitate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、支持体の片面に粘着剤
層が設けられた医療用粘着テープもしくはシートに関
し、より詳細には、粘着性を損なうことなく貼付時の透
湿性を付与し、さらに剥離時の毛むしりや皮膚角質剥離
などの物理的刺激の殆どない低刺激性の医療用粘着テー
プもしくはシートに関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a medical pressure-sensitive adhesive tape or sheet having a pressure-sensitive adhesive layer provided on one side of a support, and more particularly to a medical pressure-sensitive adhesive tape or sheet which imparts moisture permeability during application without impairing the adhesiveness. The present invention also relates to a low-irritation medical pressure-sensitive adhesive tape or sheet having little physical irritation such as scalp and exfoliation of the skin during peeling.
【0002】[0002]
【従来の技術】一般に、医療用プラスター、絆創膏、手
術用ドレシングなどの医療用粘着テープもしくはシート
は、粘着剤として天然ゴムやポリイソプレンゴムなどの
ゴム弾性体と粘着付与樹脂と軟化剤を配合してなるゴム
系粘着剤を用いたものである。しかしこのようなゴム弾
性体を主体とする粘着剤層を備えた医療用粘着テープも
しくはシートは、貼付時の粘着性が優れている反面、剥
離時にはその強い粘着力のために皮膚の角質層を剥離
し、体毛の毛むしりを招き、また透湿性がないため皮膚
にかぶれを生じさせ、炎症を来たした。2. Description of the Related Art Generally, medical pressure-sensitive adhesive tapes or sheets for medical plasters, bandages, surgical dressings, and the like are prepared by blending a rubber elastic material such as natural rubber or polyisoprene rubber, a tackifying resin, and a softener as a pressure-sensitive adhesive. Using a rubber-based pressure-sensitive adhesive. However, a medical pressure-sensitive adhesive tape or sheet having a pressure-sensitive adhesive layer mainly composed of such a rubber elastic body has excellent adhesiveness at the time of application, but has a horny layer of skin due to its strong adhesive strength at the time of peeling. It exfoliated, leading to hair swelling and lack of moisture permeability, causing skin irritation and irritation.
【0003】そこで、皮膚に対する刺激を和らげる方法
として、以下のような構成の医療用粘着テープもしくは
シートが提案された。Therefore, as a method of reducing irritation to the skin, a medical adhesive tape or sheet having the following configuration has been proposed.
【0004】例えば、特公昭54−44688号公報に
は、プロピレングリコール、ブチレングリコール、ヘキ
シレングリコール、分子量1000以下のポリエチレン
グリコール、グリセリン、ソルビトールのような水溶性
ポリオールと、水溶性または水膨潤性高分子とをゴム系
粘着剤に配合することが提案され、また特開平1−29
7069号公報には、重量の10倍以上の水を吸収して
ゲル化膨潤する吸水性高分子(例えば、水溶性ポリマー
に架橋結合を導入したもの、具体例:三洋化成社製、サ
ンウェットIM−300、サンウェットIM−1000
MPS)をゴム系粘着剤に配合することが提案されてい
る。For example, Japanese Patent Publication No. 54-44688 discloses a water-soluble polyol such as propylene glycol, butylene glycol, hexylene glycol, polyethylene glycol having a molecular weight of 1,000 or less, glycerin and sorbitol, and a water-soluble or water-swellable high water-soluble polyol. It has been proposed to mix molecules with a rubber-based pressure-sensitive adhesive.
Japanese Patent No. 7069 discloses a water-absorbing polymer that absorbs water at least ten times its weight and gels and swells (for example, a water-soluble polymer obtained by introducing a cross-linking bond, specific examples: Sanyo Chemical Co., Ltd., Sunwet IM) -300, Sunwet IM-1000
It has been proposed to mix MPS) with a rubber-based pressure-sensitive adhesive.
【0005】[0005]
【発明が解決しようとする課題】ゴム系粘着剤を用いた
医療用粘着テープもしくはシートでは、上述したよう
に、貼付時の蒸れによるかぶれや皮膚刺激が問題であっ
た。また、上記提案のようにゴム系粘着剤に水溶性ポリ
オールを配合した場合、両者の相溶性が悪いため、ゴム
系粘着剤からポリオールがブリードする欠点があった。
さらにゴム系粘着剤に吸水性高分子を配合した場合、貼
付中は吸水性高分子が吸水して撥水しないため、吸水膨
潤し体積が膨張し使用中に貼付性が低下するといった問
題があった。As described above, a medical pressure-sensitive adhesive tape or sheet using a rubber-based pressure-sensitive adhesive has a problem of rash and skin irritation due to stuffiness at the time of application. In addition, when a water-soluble polyol is blended with a rubber-based pressure-sensitive adhesive as described above, there is a drawback that the polyol bleeds from the rubber-based pressure-sensitive adhesive due to poor compatibility between the two.
Furthermore, when a water-absorbing polymer is added to the rubber-based adhesive, there is a problem that the water-absorbing polymer absorbs water during application and does not repel water. Was.
【0006】本発明の目的は、ゴム系粘着剤の粘着性を
損なうことなくゴム系粘着剤に透湿性を付与することに
より皮膚への刺激を和らげた低刺激性の透湿性医療用粘
着テープもしくはシートを提供することである。An object of the present invention is to provide a low-irritation moisture-permeable medical pressure-sensitive adhesive tape which alleviates skin irritation by imparting moisture permeability to the rubber-based adhesive without impairing the adhesiveness of the rubber-based adhesive. Is to provide a sheet.
【0007】[0007]
【課題を解決するための手段】本願発明者らは、従来の
医療用粘着テープもしくはシートにおける上記問題点を
克服すべく鋭意検討した結果、特定のゴム系粘着剤に水
溶性高分子および多価アルコールの脂肪酸エステルを所
要量ずつ配合することにより、これら配合物質の粘着剤
に対する相溶性がよく、また粘着剤に吸湿能を持たすこ
とにより透湿性の付与が可能になり、さらにゴム系粘着
剤組成についてはスチレン系熱可塑性エラストマーに特
定のパラフィン系および/またはナフテン系炭化水素な
らびに粘着付与樹脂を配合することにより、剥離時の毛
むしりや皮膚角質剥離などの物理的刺激が殆どない医療
用粘着テープもしくはシートが得られるという知見を得
て、本発明を完成した。Means for Solving the Problems The inventors of the present application have made intensive studies to overcome the above-mentioned problems in the conventional medical pressure-sensitive adhesive tapes or sheets, and as a result, have found that a specific rubber-based pressure-sensitive adhesive has a water-soluble polymer and a polyvalent. By blending the required amount of the fatty acid ester of the alcohol, the compatibility of these compounds with the pressure-sensitive adhesive is good, and the pressure-sensitive adhesive has a moisture-absorbing ability, so that moisture permeability can be imparted. For medical adhesive tapes, there is almost no physical irritation such as shavings and exfoliation of the skin by blending a specific paraffinic and / or naphthenic hydrocarbon and a tackifying resin into a styrenic thermoplastic elastomer. Alternatively, the present inventors have found that a sheet can be obtained, and have completed the present invention.
【0008】すなわち、本発明による医療用粘着テープ
もしくはシートは、支持体の片面に粘着剤層が設けられ
た医療用粘着テープもしくはシートにおいて、該粘着剤
層が、A−B−A型ブロック共重合体からなるスチレン
系熱可塑性エラストマーを5〜25重量%、炭素数10
〜30のパラフィン系および/またはナフテン系炭化水
素と粘着付与樹脂とを75〜95重量%含有するゴム系
粘着剤と、粘着剤層中に配合された水溶性高分子2〜3
0重量%および多価アルコールの脂肪酸エステル2〜3
0重量%とからなるものである。That is, the medical pressure-sensitive adhesive tape or sheet according to the present invention is a medical pressure-sensitive adhesive tape or sheet in which a pressure-sensitive adhesive layer is provided on one surface of a support, wherein the pressure-sensitive adhesive layer is an ABA-type block. 5 to 25% by weight of a styrene-based thermoplastic elastomer made of a polymer and having 10 carbon atoms
A rubber-based pressure-sensitive adhesive containing 75 to 95% by weight of a paraffinic and / or naphthenic hydrocarbon and a tackifier resin, and a water-soluble polymer compounded in the pressure-sensitive adhesive layer.
0% by weight and fatty acid ester of polyhydric alcohol 2-3
0% by weight.
【0009】以下、本発明による消炎鎮痛医療用粘着テ
ープもしくはシートの各構成成分、製造法等について詳
述する。Hereinafter, each component of the anti-inflammatory and analgesic medical pressure-sensitive adhesive tape or sheet according to the present invention, its production method, and the like will be described in detail.
【0010】a) ゴム系粘着剤の一構成成分であるA
−B−A型ブロック共重合体からなるスチレン系熱可塑
性エラストマーとしては、スチレン−イソプレン−スチ
レンブロック共重合体(溶液粘度:300〜2000c
P(25重量%トルエン溶液);スチレン/ゴム重量
比:14/86〜21/79)、スチレン−ブタジエン
−スチレンブロック共重合体(溶液粘度:220〜40
0cP(25重量%トルエン溶液);スチレン/ゴム重
量比:28/72〜50/50)、スチレン−エチレン
/ブチレン−スチレンブロック共重合体(溶液粘度:2
00〜1500cP(20重量%トルエン溶液);スチ
レン/ゴム重量比:13/87〜30/70)などが用
いられる。A) A which is one component of the rubber-based pressure-sensitive adhesive
As a styrene-based thermoplastic elastomer composed of a -BA type block copolymer, a styrene-isoprene-styrene block copolymer (solution viscosity: 300 to 2,000 c.
P (25 wt% toluene solution); styrene / rubber weight ratio: 14 / 86-21 / 79), styrene-butadiene-styrene block copolymer (solution viscosity: 220-40)
0cP (25% by weight toluene solution); styrene / rubber weight ratio: 28/72 to 50/50), styrene-ethylene / butylene-styrene block copolymer (solution viscosity: 2)
00 to 1500 cP (20% by weight toluene solution); styrene / rubber weight ratio: 13/87 to 30/70).
【0011】ゴム系粘着剤中のスチレン系熱可塑性エラ
ストマーの割合は5〜25重量%である。この割合が5
重量%より少ないと、ゴム系粘着剤の凝集力が低いた
め、充分な貼付性が得られず、剥離時に糊残りなどが生
じる。また、ゴム系粘着剤中のスチレン系熱可塑性エラ
ストマーの割合が25重量%より多いと、ゴム系粘着剤
の粘着力が強くなりすぎるため、繰り返し貼付ができ
ず、剥離時に角質剥離や毛むしりが生じ、刺激性が大き
くなる。The proportion of the styrene thermoplastic elastomer in the rubber pressure-sensitive adhesive is 5 to 25% by weight. This ratio is 5
When the amount is less than the weight%, the cohesive force of the rubber-based pressure-sensitive adhesive is low, so that sufficient adhesiveness cannot be obtained, and adhesive residue or the like occurs at the time of peeling. On the other hand, if the proportion of the styrene-based thermoplastic elastomer in the rubber-based pressure-sensitive adhesive is more than 25% by weight, the adhesive strength of the rubber-based pressure-sensitive adhesive becomes too strong, so that repeated application cannot be performed, and exfoliation and scalping during peeling may occur. It causes irritation.
【0012】本発明で用いられる炭素数10〜30のパ
ラフィン系炭化水素および(または)ナフテン系炭化水
素としては、軽質流動パラフィン、重質流動パラフィ
ン、ヘキサメチルテトラコサン、ヘキサメチルテトラコ
サヘキサン、α−オレフィンオリゴマーなどが例示さ
れ、これらが単独でもしくは2以上の組み合わせで用い
られる。The paraffinic and / or naphthenic hydrocarbons having 10 to 30 carbon atoms used in the present invention include light liquid paraffin, heavy liquid paraffin, hexamethyltetracosane, hexamethyltetracosahexane, α -Olefin oligomers, etc., which are used alone or in combination of two or more.
【0013】炭素数31以上のパラフィン系炭化水素お
よび(または)ナフテン系炭化水素は、室温で固形であ
り、粘着付与樹脂やスチレン系熱可塑性エラストマーと
の配合時に十分な軟化性がないために、良好な粘着力を
有する貼付剤は得られない。炭素数9以下のものは、軟
化性が高くなり粘着剤層が柔らかくなりすぎるため、好
ましくない。Paraffinic hydrocarbons and / or naphthenic hydrocarbons having 31 or more carbon atoms are solid at room temperature and do not have sufficient softening properties when compounded with a tackifier resin or a styrene-based thermoplastic elastomer. A patch having good adhesive strength cannot be obtained. Those having 9 or less carbon atoms are not preferred because the softening property is increased and the pressure-sensitive adhesive layer becomes too soft.
【0014】本発明に用いられる粘着付与樹脂として
は、ロジン系樹脂(ロジン、水添ロジン、これらのエス
テルなど)、ポリテルペン樹脂、クマロン−イソデン樹
脂、石油系樹脂(脂肪族系、脂環族系など)、テルペン
−フェノール樹脂などの群より選ばれた、軟化点50〜
130℃のものが例示され、これらが単独でもしくは2
以上の組み合わせで用いられる。とりわけ、石油樹脂の
脂環族炭化水素樹脂(軟化点65〜130℃)、水添ロ
ジンのグリセリンエステル(軟化点80〜130℃)、
ポリテルペン樹脂(軟化点80〜130℃)などが好ま
しい。The tackifying resin used in the present invention includes rosin resins (rosin, hydrogenated rosin, esters thereof and the like), polyterpene resins, cumarone-isodene resins, and petroleum resins (aliphatic and alicyclic resins). ), A softening point of at least 50 selected from the group of terpene-phenol resin, etc.
130 ° C. are exemplified.
Used in combination above. Above all, alicyclic hydrocarbon resin of petroleum resin (softening point of 65 to 130 ° C), glycerin ester of hydrogenated rosin (softening point of 80 to 130 ° C),
Polyterpene resins (softening point 80 to 130 ° C.) are preferred.
【0015】粘着付与樹脂の配合割合は、貼付時の粘着
力や剥離時の毛むしりなどが起こらないように適宜決定
される。上記石油系樹脂は、ナフサ分解の際に得られる
C5留分およびC9 留分に含まれているジオレフィンや
モノオレフィン類などを一般にフリーデルクラフト型触
媒の存在下にカチオン重合することによって製造される
もので、分子量500〜2,000のものが好ましく使
用される。The mixing ratio of the tackifier resin is appropriately determined so that the adhesive force at the time of application and the scalping at the time of peeling do not occur. The petroleum resin by cationic polymerization in the presence of a generally Friedel-Crafts type catalyst such as di-olefins and mono-olefins contained in the C 5 fraction and C 9 fraction obtained in the naphtha cracking Those manufactured and having a molecular weight of 500 to 2,000 are preferably used.
【0016】本発明による医療用粘着テープもしくはシ
ートのさらに好適な態様においては、パラフィン系炭化
水素および/またはナフテン系炭化水素と粘着付与樹脂
とは、重量比2:3〜3:2の範囲で配合される。その
理由は、パラフィン系炭化水素および/またはナフテン
系炭化水素と粘着付与樹脂との重量比が3:2より大き
い場合は、粘着性が不充分となったり、剥離後に糊残り
が生じたりし易いからであり、逆に、該重量比が2:3
よりも小さい場合には、剥離時に毛むしりが生じたり、
皮膚の角質層が剥離し皮膚刺激が起こり易いからであ
る。In a further preferred embodiment of the medical pressure-sensitive adhesive tape or sheet according to the present invention, the paraffinic hydrocarbon and / or the naphthenic hydrocarbon and the tackifying resin are in a weight ratio of 2: 3 to 3: 2. Be blended. The reason is that when the weight ratio of the paraffin-based hydrocarbon and / or the naphthenic-based hydrocarbon to the tackifying resin is more than 3: 2, the tackiness becomes insufficient or the adhesive residue easily occurs after peeling. And conversely, the weight ratio is 2: 3
If it is smaller than the above, swelling may occur at the time of peeling,
This is because the stratum corneum of the skin peels off and skin irritation easily occurs.
【0017】粘着剤層中に配合される水溶性高分子とし
ては、メチルセルロース、ヒドロキシプロピルセルロー
ス、ヒドロキシプロピルメチルセルロース、ヒドロキシ
エチルセルロース、カルボキシメチルセルロース、カル
ボキシメチルセルロースナトリウム、結晶セルロース・
カルボキシメチルセルロースナリウムなどの水溶性のセ
ルロース誘導体、デンプン、アルファー化デンプン、デ
キストリン、シクロデキストリン、プルラン、ヒドロキ
シプロピルスターチ、カルボキシメチルスターチナトリ
ウムなどのデンプンまたはその誘導体、ポリビニルピロ
リドン、カルボキシビニルポリマー、ポリビニルアルコ
ールなどの水溶性合成高分子、アラビアゴム、アルギン
酸ナトリウム、アルギン酸プロピレングリコールエステ
ル、キサンタンガム、ゼラチンなどの水溶性天然高分子
などが例示される。Examples of the water-soluble polymer to be incorporated in the pressure-sensitive adhesive layer include methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose.
Water-soluble cellulose derivatives such as carboxymethylcellulose narium, starch or starch such as starch, pregelatinized starch, dextrin, cyclodextrin, pullulan, hydroxypropyl starch, sodium carboxymethyl starch, or derivatives thereof, polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl alcohol, etc. And water-soluble natural polymers such as gum arabic, sodium alginate, propylene glycol alginate, xanthan gum, gelatin and the like.
【0018】水溶性高分子の粒子径は、粘着剤溶液への
配合時に均一な分散物を得るために、500μm以下、
さらには200μm以下であることが好ましい。The particle size of the water-soluble polymer is 500 μm or less in order to obtain a uniform dispersion when compounded in the pressure-sensitive adhesive solution.
More preferably, it is 200 μm or less.
【0019】水溶性高分子の配合量は、粘着剤層中に2
〜30重量%である。この配合量が2%未満であると貼
付剤に充分な透湿性が得られず、逆にこの配合量が30
重量%を越えると粘着剤への配合が困難であったり、貼
付性が劣るなどの問題が生じる。適度の透湿性と貼付性
を確保するには、水溶性高分子の配合量は好ましくは4
〜25重量%である。The compounding amount of the water-soluble polymer is 2 in the pressure-sensitive adhesive layer.
3030% by weight. If the amount is less than 2%, the patch may not have sufficient moisture permeability, and if the amount is less than 30%,
If the content is more than 10% by weight, problems such as difficulty in compounding the composition into the pressure-sensitive adhesive and poor sticking properties arise. In order to ensure proper moisture permeability and sticking property, the amount of the water-soluble polymer is preferably 4
2525% by weight.
【0020】粘着剤層中に配合される多価アルコールの
脂肪酸エステルは、ゴム系粘着剤と相溶可能なものであ
り、その具体例としては、ソルビタンカプレート、ソル
ビタンラウレート、ソルビタンパルミテート、ソルビタ
ンステアレート、ソルビタンオレエートなどのソルビタ
ン脂肪酸エステル、グリセリンカプレート、グリセリン
ミリステート、グリセリンステアレート、グリセリンモ
ノオレエート、デカグリセリンラウレート、デカグリセ
リンミリスレート、デカグリセリンステアレート、デカ
グリセリンオレエート、ジグリセリルステアレート、ジ
グリセリルオレエート、テトラグリセリルステアレー
ト、テトラグリセリルオレエート、ヘキサグリセリルス
テアレート、ヘキサグリセリルオレエート、ヘキサグリ
セリルミリステート、ヘキサグリセリルラウレートなど
のグリセリン脂肪酸エステル、プロピレングリコールス
テアリートなどのプロピレングリコール脂肪酸エステ
ル、ポリオキシエチレンソルビタンステアレートなどの
ポリオキシエチレンソルビタン脂肪酸エステル、ポリオ
キシエチレングリセリルオレエートなどのポリオキシエ
チレングリセリン脂肪酸エステル、ポリエチレングリコ
ールステアレートなどのポリエチレングリコール脂肪酸
エステルが挙げられる。The fatty acid ester of the polyhydric alcohol compounded in the pressure-sensitive adhesive layer is compatible with the rubber-based pressure-sensitive adhesive, and specific examples thereof include sorbitanca plate, sorbitan laurate, sorbitan palmitate, and the like. Sorbitan stearate, sorbitan fatty acid esters such as sorbitan oleate, glycerin caprate, glycerin myristate, glycerin stearate, glycerin monooleate, decaglycerin laurate, decaglycerin myristate, decaglycerin stearate, decaglycerin oleate, Diglyceryl stearate, diglyceryl oleate, tetraglyceryl stearate, tetraglyceryl oleate, hexaglyceryl stearate, hexaglyceryl oleate, hexaglyceryl myristate Glycerin fatty acid esters such as hexaglyceryl laurate, propylene glycol fatty acid esters such as propylene glycol stearate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan stearate, and polyoxyethylene glycerin fatty acid esters such as polyoxyethylene glyceryl oleate And polyethylene glycol fatty acid esters such as polyethylene glycol stearate.
【0021】多価アルコールの脂肪酸エステルの配合量
は、粘着剤層中に2〜30重量%である。この配合量が
2%未満であると貼付剤に充分な透湿性が得られず、逆
にこの配合量が30重量%を越えるとこれが粘着剤層か
らブリードしたり、貼付性がが劣るなどの問題が生じ
る。適度の透湿性と貼付性を確保するには、多価アルコ
ールの脂肪酸エステルの配合量は好ましくは4〜25重
量%である。こうして、水溶性高分子および多価アルコ
ールの脂肪酸エステルを粘着剤層中に含有せしめること
により、貼付剤に充分な透湿性が得られる。透湿度は、
60g/m2 ・24hr.未満であると、貼付感として
蒸れを感じるので、60g/m2 ・24hr.以上とな
るように構成される。 The amount of the fatty acid ester of the polyhydric alcohol is 2 to 30% by weight in the pressure-sensitive adhesive layer. If the amount is less than 2%, sufficient moisture permeability cannot be obtained for the patch, while if the amount exceeds 30% by weight, it may bleed from the pressure-sensitive adhesive layer or have poor sticking properties. Problems arise. In order to ensure appropriate moisture permeability and sticking property, the compounding amount of the fatty acid ester of the polyhydric alcohol is preferably 4 to 25% by weight. In this way, by allowing the water-soluble polymer and the fatty acid ester of the polyhydric alcohol to be contained in the pressure-sensitive adhesive layer, sufficient adhesiveness to the patch can be obtained. The moisture permeability is
60 g / m 2 · 24 hr. If it is less than 60 g / m 2 · 24 hr. More and I
It is configured to be.
【0022】b) 本発明による医療用粘着テープもし
くはシートは、薬剤を含有せずに、絆創膏、手術用ドレ
ープ、テーピング用テープなどとして用いられるが、こ
の他に必要に応じて薬物を含有していてもよい。B) The medical pressure-sensitive adhesive tape or sheet according to the present invention is used as an adhesive plaster, a surgical drape, a taping tape, etc. without containing a drug, and further contains a drug as required. You may.
【0023】薬物としては、経皮または経粘膜投与によ
り生体膜を透過しうるものが、特に限定なく適用でき、
たとえば、解熱消炎鎮痛剤、ステロイド系抗炎症剤、血
管拡張剤、高血圧・不整脈用剤、血圧降下剤、鎮咳去
痰、抗腫瘍剤、局所麻酔剤、ホルモン剤、喘息、アレル
ギー性鼻炎治療剤、抗ヒスタミン剤、抗凝血剤、鎮けい
剤、脳循環・代謝改善剤、抗うつ・抗不安剤、ビタミン
製剤、経口血糖降下剤、抗潰瘍剤、睡眠剤、抗生物質、
皮膚刺激薬などが例示される。As the drug, those which can penetrate a biological membrane by transdermal or transmucosal administration can be applied without particular limitation.
For example, antipyretic antiphlogistic analgesics, steroidal anti-inflammatory drugs, vasodilators, hypertension / arrhythmia drugs, antihypertensive drugs, antitussive expectorants, antitumor drugs, local anesthetics, hormonal drugs, asthma, allergic rhinitis treatment drugs, antihistamines , Anticoagulants, anticonvulsants, cerebral circulation / metabolic improvers, antidepressants / anxiolytics, vitamin preparations, oral hypoglycemic agents, antiulcer agents, sleeping pills, antibiotics,
Examples include skin irritants.
【0024】解熱消炎鎮痛剤としては、サリチル酸、サ
リチル酸メチル、サリチル酸グリコール、グリチルレチ
ン酸、グリチルリチン酸、インドメタシン、ケトプロフ
ェン、フルルビプロフェン、アンフェナックなどがあ
る。Examples of the antipyretic and antiphlogistic analgesic include salicylic acid, methyl salicylate, glycol salicylate, glycyrrhetinic acid, glycyrrhizic acid, indomethacin, ketoprofen, flurbiprofen, ampfenac and the like.
【0025】抗ヒスタミン剤としては、ジフェンヒドラ
ミン、塩酸ジフェンヒドラミン、マレイン酸クロルフェ
ニラミンなどがある。The antihistamines include diphenhydramine, diphenhydramine hydrochloride, chlorpheniramine maleate and the like.
【0026】皮膚刺激薬としては、メントール、ハッカ
油、カンフル、ノニル酸ワニリルアミド、ニコチン酸ベ
ンジル、ニコチン酸β−ブトキシエチル、トウガラシ
(エキス)、カプサイシン、サンシシ(エキス)などが
ある。Examples of the skin irritants include menthol, peppermint oil, camphor, vanillyl amide nonylate, benzyl nicotinate, β-butoxyethyl nicotinate, pepper (extract), capsaicin, and sanshishi (extract).
【0027】血管拡張剤としては、硝酸イソソルビド、
4硝酸ペンタエリスリトール、ニフェジピンなどがあ
る。As vasodilators, isosorbide dinitrate,
Pentaerythritol tetranitrate, nifedipine and the like.
【0028】薬物の添加量については、粘着剤層全体に
対し薬物を30重量%までの割合で配合することが可能
である。その理由は、薬物の配合量が30重量%を超え
ると、上述した粘着剤の機能が損なわれ、充分な貼付性
および皮膚に対する低刺激性を満足させることができな
くなるからである。With respect to the amount of drug added, it is possible to add the drug in a proportion of up to 30% by weight based on the whole pressure-sensitive adhesive layer. The reason is that if the compounding amount of the drug exceeds 30% by weight, the function of the above-mentioned pressure-sensitive adhesive is impaired, and it becomes impossible to satisfy sufficient adhesiveness and low irritation to the skin.
【0029】c) 本発明による医療用粘着テープもし
くはシートの粘着剤層中には、必要に応じて液状ポリマ
ー成分が配合される。液状ポリマー成分としては、ポリ
イソブチレン、ポリブテンまたは液状ポリイソプレンな
ど、A−B−A型ブロック共重合体からなるスチレン系
熱可塑性エラストマーと相溶可能なものが使用される。
貼付性の観点からは、液状ポリマー成分としてポリブテ
ンが好適である。液状ポリマー成分の添加量は、ゴム系
粘着剤中に10重量%以下であることが好ましい。その
理由は、この添加量が10重量%を越えると、充分な貼
付性および皮膚に対する充分な低刺激性を確保すること
ができないからである。C) In the pressure-sensitive adhesive layer of the pressure-sensitive adhesive tape or sheet for medical use according to the present invention, a liquid polymer component is blended if necessary. As the liquid polymer component, one that is compatible with a styrene-based thermoplastic elastomer made of an ABA block copolymer, such as polyisobutylene, polybutene, or liquid polyisoprene, is used.
From the viewpoint of sticking properties, polybutene is preferred as the liquid polymer component. The addition amount of the liquid polymer component is preferably 10% by weight or less in the rubber-based pressure-sensitive adhesive. The reason for this is that if the added amount exceeds 10% by weight, it is not possible to ensure sufficient sticking properties and sufficient low irritation to the skin.
【0030】また、本発明による医療用粘着テープもし
くはシートにおける粘着剤層中には、上記薬物や液状ポ
リマー成分の他に、酸化防止剤、充填剤などを、本発明
の作用効果を阻害しない限り、適宜添加してもよい。In the pressure-sensitive adhesive layer of the pressure-sensitive adhesive tape or sheet for medical use according to the present invention, in addition to the above-mentioned drug and liquid polymer component, an antioxidant, a filler and the like are used as long as they do not impair the effects of the present invention. May be appropriately added.
【0031】d) 本発明に用いられる支持体の材質と
しては、不織布、織布、ポリエステル、ポリエチレン、
ポリ塩化ビニル、ポリ塩化ビニリデン、エチレン−酢酸
ビニル共重合体、ポリウレタン、有孔アルミニウム箔お
よびこれらのラミネートフィルムなどが例示される。こ
れらの中で透湿性の低い材質にあっては、これに物理化
学的な加工処理を施して透湿性を付与するのが好まし
い。この処理は皮膚の蒸れすぎによるかぶれを防ぐため
である。また、上記支持体は少なくとも一方向に伸縮す
る機能を有するものであることが望ましく、かかる機能
を有しない材質のものには適宜の伸縮付与加工を施すの
がよい。支持体が伸縮機能を有すると、医療用粘着テー
プもしくはシートを身体に貼付したときに皮膚面の伸縮
に追従させることができるからである。支持体の厚みは
好ましくは5〜2,000μmである。D) As the material of the support used in the present invention, non-woven fabric, woven fabric, polyester, polyethylene,
Examples thereof include polyvinyl chloride, polyvinylidene chloride, ethylene-vinyl acetate copolymer, polyurethane, perforated aluminum foil, and a laminate film thereof. Among these materials, it is preferable that a material having low moisture permeability is subjected to physicochemical processing to impart moisture permeability. This treatment is to prevent rash due to excessive stuffiness of the skin. Further, the support preferably has a function of expanding and contracting in at least one direction, and a material having no such function is preferably subjected to an appropriate expansion / contraction process. This is because if the support has a stretching function, it can follow the stretching of the skin surface when the medical adhesive tape or sheet is applied to the body. The thickness of the support is preferably 5 to 2,000 μm.
【0032】e) 本発明に用いられる後述の剥離紙と
しては、ポリエステル、ポリプロピレン、ポリエチレン
コート上質紙、ポリエチレンコートグラシン紙などの上
面にシリコン処理を施したものなどが例示される。剥離
紙の厚みは好ましくは20〜200μmである。E) Examples of the release paper described later used in the present invention include polyester, polypropylene, polyethylene-coated high-quality paper, polyethylene-coated glassine paper, and the like whose upper surface is subjected to silicon treatment. The thickness of the release paper is preferably 20 to 200 μm.
【0033】f) 本発明による医療用粘着テープもし
くはシートを製造する方法の代表例としては、溶剤法、
ホットメルト法が挙げられる。F) Representative examples of the method for producing the medical pressure-sensitive adhesive tape or sheet according to the present invention include a solvent method,
Hot melt method is mentioned.
【0034】溶剤法では、ゴム系粘着剤に、水溶性高分
子および多価アルコールの脂肪酸エステルを加え、さら
に必要に応じて薬物成分および/または液状ポリマー成
分、その他の添加剤を加え、これらを均一に溶解ないし
は分散する。用いられる溶媒の例としては、ゴム系粘着
剤、薬物その他と相溶性があるもの、例えば、テトラヒ
ドロフラン、クロロホルム、塩化メチレンが挙げられ
る。ただし、水溶性高分子のうちポリビニルピロリドン
はアルコール系溶剤でなければ溶けにくいので、先にこ
れをメタノールなどに溶かした後、他の成分と混合する
とよい。こうして得られた溶液ないしは分散液を剥離紙
(または支持体)上に展延し、乾燥を施して溶剤を除去
し、得られた粘着剤層上に支持体(または剥離紙)をラ
ミネートする。In the solvent method, a water-soluble polymer and a fatty acid ester of a polyhydric alcohol are added to a rubber-based pressure-sensitive adhesive, and if necessary, a drug component and / or a liquid polymer component and other additives are added. Dissolve or disperse uniformly. Examples of the solvent used include those that are compatible with rubber-based pressure-sensitive adhesives, drugs, and the like, for example, tetrahydrofuran, chloroform, and methylene chloride. However, among the water-soluble polymers, polyvinylpyrrolidone is difficult to dissolve unless it is an alcohol-based solvent. Therefore, it is advisable to first dissolve this in methanol or the like and then mix it with other components. The solution or dispersion thus obtained is spread on release paper (or support), dried to remove the solvent, and the support (or release paper) is laminated on the obtained pressure-sensitive adhesive layer.
【0035】また、ホットメルト法を適用する場合は、
ゴム系粘着剤、水溶性高分子および多価アルコールの脂
肪酸エステル、必要に応じて液状ポリマー成分、その他
の添加剤を所定量ずつ配合し、配合物を窒素置換下、温
度120〜150℃で加熱混合して溶融する。溶融後、
粘着剤の温度を100〜120°に降下し、さらに必要
に応じて加えられる薬物成分を添加し、均一に混合し
て、溶融状態の溶液を得る。ついで、この溶液を、ホッ
トメルトコーターを用いて、剥離紙(または支持体)上
に展延し、得られた粘着剤層上に支持体(または剥離
紙)をラミネートする。When the hot melt method is applied,
A predetermined amount of a rubber-based adhesive, a water-soluble polymer and a fatty acid ester of a polyhydric alcohol, a liquid polymer component, and other additives are blended in predetermined amounts, and the blend is heated at a temperature of 120 to 150 ° C. under a nitrogen atmosphere. Mix and melt. After melting,
The temperature of the pressure-sensitive adhesive is lowered to 100 to 120 [deg.], And if necessary, a drug component is added and mixed uniformly to obtain a solution in a molten state. Next, this solution is spread on a release paper (or a support) using a hot melt coater, and the support (or a release paper) is laminated on the obtained pressure-sensitive adhesive layer.
【0036】[0036]
【発明の効果】本発明は以上の如く構成されているの
で、ゴム系粘着剤の粘着性を損なうことなく貼付時の透
湿性を付与し、さらに剥離時の毛むしりや皮膚角質剥離
などの物理的刺激の殆どない低刺激性の医療用粘着テー
プもしくはシートを提供することができる。Since the present invention is constituted as described above, it imparts moisture permeability at the time of sticking without impairing the adhesiveness of the rubber-based pressure-sensitive adhesive. It is possible to provide a low-irritant medical pressure-sensitive adhesive tape or sheet having almost no stimulus.
【0037】[0037]
【実施例】以下に、本発明の実施例を記載する。EXAMPLES Examples of the present invention will be described below.
【0038】実施例1〜12および比較例1〜10 薬物以外の成分を、表1〜表5に示す割合で配合し、得
られた配合物を窒素置換下で120〜160℃の温度で
加熱攪拌し、溶融した。溶融後、温度を100〜120
℃に降下し、薬物を添加し、均一混合により溶液を得
た。なお、実施例1では、薬物が含有されていないた
め、上記加熱攪拌後、配合物を溶融することにより、溶
液を得た。Examples 1 to 12 and Comparative Examples 1 to 10 Ingredients other than the drug were blended in the proportions shown in Tables 1 to 5, and the resulting blend was heated at a temperature of 120 to 160 ° C. under nitrogen substitution. Stir and melt. After melting, set the temperature to 100-120
C., the drug was added, and a solution was obtained by homogeneous mixing. In addition, in Example 1, since no drug was contained, the mixture was melted after the heating and stirring to obtain a solution.
【0039】次に、ホットメルトコーターを用いて溶融
状態の溶液を、冷却後の厚みが約200μmとなるよう
ポリエチレンコート上質紙からなる剥離紙上に展延し、
ついで粘着剤層上に支持体として厚み30μmのポリウ
レタンフィルムをラミネートした。こうして実施例1〜
12の医療用粘着テープを得た。Next, using a hot melt coater, the solution in a molten state is spread on a release paper made of polyethylene-coated high-quality paper so that the thickness after cooling becomes about 200 μm.
Next, a 30 μm-thick polyurethane film was laminated on the adhesive layer as a support. Thus, Examples 1 to
Twelve medical adhesive tapes were obtained.
【0040】上記と同様にして表6〜表9に示す配合で
比較例1〜10の医療用粘着テープを作製した。In the same manner as above, medical adhesive tapes of Comparative Examples 1 to 10 were prepared with the formulations shown in Tables 6 to 9.
【0041】[0041]
【表1】 [Table 1]
【表2】 [Table 2]
【表3】 [Table 3]
【表4】 [Table 4]
【表5】 [Table 5]
【表6】 [Table 6]
【表7】 [Table 7]
【表8】 [Table 8]
【表9】 なお、表1〜表9において、使用した成分の詳細は以下
のとおりである。[Table 9] The details of the components used in Tables 1 to 9 are as follows.
【0042】SIS:スチレン−イソプレン−スチレン
ブロック共重合体 商品名 カリフレックスTR1107(溶液粘度:約1
600cP(25重量%トルエン溶液);スチレン/ゴ
ム重量比:14/86(シェル化学社製)) 粘着付与樹脂:脂環族飽和炭化水素樹脂 商品名 アルコンP−90(軟化点90℃、荒川化学工
業社製) 重質流動パラフィン(日興製薬社製) ポリブテン 商品名 日石ポリブテン(平均分子量約1350)(日
本石油化学社製) 水溶性高分子 ポリビニルピロリドン 商品名 コリドンK90(BASF社製) ポリビニルアルコール 商品名 P.V.A C−17(信越化学社製) メチルセルロース 商品名 メトローズ SM−15(信越化学社製) トウモロコシデンプン (和光純薬工業社製) 多価アルコールの脂肪酸エステル グリセリンモノステアレート 商品名 グリセリンモノステアレート MGS−B(日
光ケミカルズ社製) ソルビタンモノステアレート 商品名 ソルビタンモノステアレート SS−10(日
光ケミカルズ社製) プロピレングリコールモノステアレート 商品名 プロピレングリコールモノステアレート PM
SIC(日光ケミカルズ社製) ポリオキシエチレンソルビタンモノステアレート 商品名 POE(6) ソルビタンモノステアレート TS
−106(日光ケミカルズ社製) ポリオキシエチレングリセリンモノステアレート 商品名 POE(5) ソルビタンモノステアレート TM
GS−5(日光ケミカルズ社製) ポリエチレングリコールモノステアレート 商品名 POE(2) モノステアレート YMS−2(日
光ケミカルズ社製) 吸水性高分子 商品名 サンウェット IM−300 MPS(三洋化
成社製) (デンプン・アクリル酸塩グラフト共重合体架橋物) 表1〜9中、SIS、重質流動パラフィン、脂環族飽和
炭化水素樹脂、ポリブテンはこれらの成分の総和に対す
る重量%で示した。また、水溶性高分子、多価アルコー
ルの脂肪酸エステル、吸水性高分子および薬物の含有量
は、粘着剤層全体に対する重量%で示した。SIS: Styrene-isoprene-styrene block copolymer (trade name: CARIFLEX TR1107 (solution viscosity: about 1)
600 cP (25 wt% toluene solution); styrene / rubber weight ratio: 14/86 (manufactured by Shell Chemical Co., Ltd.)) Tackifying resin: alicyclic saturated hydrocarbon resin Trade name Archon P-90 (softening point 90 ° C., Arakawa Chemical) Heavy liquid paraffin (manufactured by Nikko Pharmaceutical Co., Ltd.) Polybutene Trade name Nisseki polybutene (average molecular weight: about 1350) (manufactured by Nippon Petrochemical Co., Ltd.) Water-soluble polymer polyvinyl pyrrolidone Trade name Kollidon K90 (manufactured by BASF) Polyvinyl alcohol Product name P. V. A C-17 (manufactured by Shin-Etsu Chemical Co., Ltd.) Methylcellulose Brand name Metrolose SM-15 (manufactured by Shin-Etsu Chemical Co., Ltd.) Corn starch (manufactured by Wako Pure Chemical Industries, Ltd.) Fatty acid ester of polyhydric alcohol glycerin monostearate Brand name glycerin monostearate MGS -B (Nikko Chemicals) Sorbitan monostearate Trade name Sorbitan monostearate SS-10 (Nikko Chemicals) Propylene glycol monostearate Trade name Propylene glycol monostearate PM
SIC (Nikko Chemicals) Polyoxyethylene sorbitan monostearate Trade name POE (6) Sorbitan monostearate TS
-106 (manufactured by Nikko Chemicals Co., Ltd.) Polyoxyethylene glycerin monostearate Trade name POE (5) Sorbitan monostearate TM
GS-5 (Nikko Chemicals) Polyethylene glycol monostearate Trade name POE (2) Monostearate YMS-2 (Nikko Chemicals) Water-absorbing polymer Trade name Sunwet IM-300 MPS (Sanyo Chemical) (Starch / Acrylate Graft Copolymer Cross-Linked Product) In Tables 1 to 9, SIS, heavy liquid paraffin, alicyclic saturated hydrocarbon resin, and polybutene are shown by weight% with respect to the total of these components. The contents of the water-soluble polymer, the fatty acid ester of polyhydric alcohol, the water-absorbing polymer and the drug are shown in% by weight based on the whole pressure-sensitive adhesive layer.
【0043】性能試験 実施例および比較例で得られた医療用粘着テープについ
て、つぎの方法で性能試験を行った。Performance Test The performance test was performed on the medical pressure-sensitive adhesive tapes obtained in Examples and Comparative Examples by the following method.
【0044】<貼付試験>実施例および比較例の各医療
用粘着テープ(3×4cm)について、下記のごとく人
の皮膚に対する貼付試験を行った。すなわち、5名(健
常人、男性)の被験者の上腕に医療用粘着テープを貼り
付け、12時間経過後に、貼付性、貼付感を評価した
後、医療用粘着テープを剥離し、糊残り、剥離時の痛み
および刺激性について各医療用粘着テープを評価した。
繰り返し回数は1回とした。この貼付試験の結果を表1
0〜表14に示す。<Adhesion Test> An adhesion test on human skin was performed on each of the medical adhesive tapes (3 × 4 cm) of Examples and Comparative Examples as follows. That is, a medical adhesive tape was applied to the upper arms of five (healthy, male) subjects, and after 12 hours, the adhesive property and the feeling of application were evaluated. Each medical adhesive tape was evaluated for pain and irritation at the time.
The number of repetitions was one. Table 1 shows the results of this sticking test.
0 to Table 14.
【0045】[0045]
【表10】 [Table 10]
【表11】 [Table 11]
【表12】 [Table 12]
【表13】 [Table 13]
【表14】 1)貼付性:12時間貼付後、医療用粘着テープが接着
している面積の試験開始時の面積に対する割合を観察し
た。[Table 14] 1) Adherability: After adhering for 12 hours, the ratio of the area to which the medical adhesive tape was adhered to the area at the start of the test was observed.
【0046】良好:貼付剤の残存接着面積が95%以上
であった 普通:貼付剤の残存接着面積が75%〜95%未満であ
った 不良:貼付剤の残存接着面積が75%未満であった。Good: The residual adhesive area of the patch was 95% or more. Normal: The residual adhesive area of the patch was 75% to less than 95%. Poor: The residual adhesive area of the patch was less than 75%. Was.
【0047】2)糊残り:剥離後、粘着剤が皮膚上に残
るか否かを評価した。 −:剥離後、粘着剤が皮膚上に残らなかった +:剥離後、粘着剤が皮膚上に残った。2) Residual adhesive: After peeling, it was evaluated whether or not the adhesive remained on the skin. -: The adhesive did not remain on the skin after peeling. +: The adhesive remained on the skin after peeling.
【0048】3)剥離時の痛さ:剥離時の痛みについて
官能試験で評価した。 −:特に痛みを感じなかった ±:わずかに痛みを感じた +:非常に痛みを感じた。3) Pain at peeling: Pain at peeling was evaluated by a sensory test. -: No particular pain was felt ±: Slight pain was felt +: Very pain was felt.
【0049】4)刺激性:剥離後、約1時間経過後の貼
付部位の皮膚の状態を肉眼により判定した。 −:変化なし ±:わずかに紅斑が認められる +:紅斑が認められる。4) Irritation: About 1 hour after peeling, the condition of the skin at the application site was visually judged. -: No change ±: Slight erythema is observed +: Erythema is observed
【0050】5)貼付感:貼付試験時の貼付感について
官能試験で評価した。 −:蒸れなし ±:わずかに蒸れあり +:蒸れあり。5) Stickiness: The stickiness at the time of the sticking test was evaluated by a sensory test. -: No humidity ±: Slightly humid +: Slightly humid
【0051】<透湿度試験>透湿度試験は、JIS Z
0208「防湿包装材料の透湿度試験方法(カップ
法)」に準じて行った。すなわち、カップに無水塩化カ
ルシウム約12gを入れ、カップの口を医療用粘着テー
プで密閉する。試験カップを40℃、相対湿度90%の
恒温恒湿槽に入れ、24時間放置後塩化カルシウムの質
量増加を測定し、透湿度(g/m2 ・24時間)を求め
た。<Moisture Permeability Test> The moisture permeability test was performed according to JIS Z
[0208] The test was carried out in accordance with "Moisture Permeability Test Method for Moistureproof Packaging Material (Cup Method)". That is, about 12 g of anhydrous calcium chloride is put in a cup, and the mouth of the cup is sealed with a medical adhesive tape. The test cup was placed in a thermo-hygrostat at 40 ° C. and a relative humidity of 90%. After standing for 24 hours, the increase in the mass of calcium chloride was measured to determine the moisture permeability (g / m 2 · 24 hours).
【0052】表10〜表14から明らかなように、実施
例の医療用粘着テープはいずれの試験項目においても優
れていることが認められる。As is clear from Tables 10 to 14, it is recognized that the medical pressure-sensitive adhesive tapes of the examples are excellent in any of the test items.
【0053】これに対し、比較例4では水溶性高分子の
添加量が30重量%以上であるため、塗工時粘着剤面が
不均一であり、貼付性が不良であり、糊残りも生じた。On the other hand, in Comparative Example 4, since the amount of the water-soluble polymer added was 30% by weight or more, the surface of the pressure-sensitive adhesive at the time of coating was non-uniform, the sticking property was poor, and adhesive residue was left. Was.
【0054】比較例5では多価アルコールの脂肪酸エス
テルとしてのグリセリンモノステアレートの添加量が3
0重量%以上であるため、グリセリンモノステアレート
が粘着剤層よりブリードし、貼付性が不良であり、糊残
りも生じた。In Comparative Example 5, the addition amount of glycerin monostearate as a fatty acid ester of polyhydric alcohol was 3
Since the content was 0% by weight or more, glycerin monostearate bleeded from the pressure-sensitive adhesive layer, adhesion was poor, and adhesive residue remained.
【0055】比較例7ではSISの添加量が25重量%
を越えるため、剥離時に痛みがあった。In Comparative Example 7, the amount of SIS added was 25% by weight.
Was painful at the time of peeling.
【0056】比較例8ではSISの添加量が5重量%未
満であるため、貼付性が不良であり、糊残りを生じた。In Comparative Example 8, since the added amount of SIS was less than 5% by weight, the sticking property was poor and adhesive residue was left.
【0057】比較例9は特公昭54−44688号公報
記載の医療用粘着テープの例であり、グリセリンが粘着
剤層よりブリードし、貼付性が不良であった。Comparative Example 9 is an example of a medical pressure-sensitive adhesive tape described in Japanese Patent Publication No. 54-44688, in which glycerin bleeded from the pressure-sensitive adhesive layer, and the adhesive property was poor.
【0058】比較例10は特開平1−297069号公
報記載の医療用粘着テープの例であり、貼付性が不良で
あった。Comparative Example 10 is an example of the medical pressure-sensitive adhesive tape described in Japanese Patent Application Laid-Open No. 1-297069, and the sticking property was poor.
───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.7,DB名) A61K 9/70 A61L 15/06 ──────────────────────────────────────────────────続 き Continued on the front page (58) Field surveyed (Int.Cl. 7 , DB name) A61K 9/70 A61L 15/06
Claims (2)
療用粘着テープもしくはシートにおいて、該粘着剤層
が、A−B−A型ブロック共重合体からなるスチレン系
熱可塑性エラストマーを5〜25重量%、炭素数10〜
30のパラフィン系および/またはナフテン系炭化水素
と粘着付与樹脂とを75〜95重量%含有するゴム系粘
着剤と、粘着剤層中に配合された水溶性高分子2〜30
重量%および多価アルコールの脂肪酸エステル2〜30
重量%とからなり(但し、該粘着剤層には無水ケイ酸が
含まれない。)、透湿度が60g/m 2 ・24hr.以
上である医療用粘着テープもしくはシート。1. A medical pressure-sensitive adhesive tape or sheet in which a pressure-sensitive adhesive layer is provided on one side of a support, wherein the pressure-sensitive adhesive layer is made of a styrene-based thermoplastic elastomer composed of an ABA block copolymer. ~ 25% by weight, carbon number 10 ~
A rubber-based pressure-sensitive adhesive containing 75 to 95% by weight of a paraffinic and / or naphthene-based hydrocarbon and a tackifier resin, and a water-soluble polymer 2 to 30 compounded in the pressure-sensitive adhesive layer.
% By weight and fatty acid ester of polyhydric alcohol 2 to 30
% By weight (provided that the pressure-sensitive adhesive layer contains silicic anhydride
Not included. ), A moisture permeability of 60 g / m 2 · 24 hr. Less than
Upper medical adhesive tape or sheet.
ナフテン系炭化水素と粘着付与樹脂との重量比が2:3
〜3:2の範囲にある請求項1記載の医療用粘着テープ
もしくはシート。2. The weight ratio of the paraffinic hydrocarbon and / or naphthenic hydrocarbon to the tackifier resin is 2: 3.
The medical pressure-sensitive adhesive tape or sheet according to claim 1, wherein the pressure-sensitive adhesive tape or sheet is in the range of ~ 3: 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17288792A JP3144895B2 (en) | 1992-06-30 | 1992-06-30 | Medical adhesive tape or sheet |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17288792A JP3144895B2 (en) | 1992-06-30 | 1992-06-30 | Medical adhesive tape or sheet |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0616542A JPH0616542A (en) | 1994-01-25 |
JP3144895B2 true JP3144895B2 (en) | 2001-03-12 |
Family
ID=15950168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP17288792A Expired - Fee Related JP3144895B2 (en) | 1992-06-30 | 1992-06-30 | Medical adhesive tape or sheet |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3144895B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002031044A1 (en) * | 2000-10-12 | 2002-04-18 | Duraban Oy | Polyalphaolefin plastisizers for elastomers |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4820495B2 (en) * | 2001-05-29 | 2011-11-24 | 株式会社トクホン | Plaster agent |
DE102009052943A1 (en) * | 2009-07-14 | 2011-05-19 | Lts Lohmann Therapie-Systeme Ag | Water vapor permeable skin patch |
JP5581534B2 (en) * | 2009-12-18 | 2014-09-03 | アルケア株式会社 | Adhesive, adhesive sheet using the adhesive, and production method thereof |
JP6309892B2 (en) * | 2012-06-20 | 2018-04-11 | 株式会社 メドレックス | A medicated patch composition comprising a drug, an organic solvent, a lipophilic plaster base and a powder. |
CN107754009A (en) * | 2016-08-18 | 2018-03-06 | 浙江海创医疗器械有限公司 | The preparation method and application method of a kind of low high viscosity water colloid of anaphylaxis |
JP2019014694A (en) * | 2017-07-10 | 2019-01-31 | 株式会社セニースタジオ | Diet patch using thermoplastic elastomer gel composition containing capsaicin |
DE102018222213A1 (en) * | 2018-12-18 | 2020-06-18 | Beiersdorf Ag | Adhesive for sticking to the skin |
-
1992
- 1992-06-30 JP JP17288792A patent/JP3144895B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002031044A1 (en) * | 2000-10-12 | 2002-04-18 | Duraban Oy | Polyalphaolefin plastisizers for elastomers |
Also Published As
Publication number | Publication date |
---|---|
JPH0616542A (en) | 1994-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU784779B2 (en) | Ultraviolet-shielding adhesive preparation | |
JP4705301B2 (en) | Patch | |
JP5597187B2 (en) | Adhesive composition and adhesive tape | |
JP6893086B2 (en) | Improved adhesive properties | |
JP5243792B2 (en) | Patch | |
JP2004520112A (en) | Hot melt adhesive applied to skin | |
JPH09100227A (en) | Solid matrix system for percutaneous drug delivery | |
TWI742331B (en) | Patch containing rotigotine | |
WO2002032431A1 (en) | Compositions for external preparations | |
JPH08295624A (en) | Plaster base, its production and patch for external use using the same base | |
JP3499247B2 (en) | Patch containing felbinac | |
JP3144895B2 (en) | Medical adhesive tape or sheet | |
JP3542814B2 (en) | Anti-inflammatory analgesic patch | |
JP3276188B2 (en) | Patch and method for producing the same | |
JPH09291028A (en) | Plaster | |
WO1998051299A1 (en) | Patches containing isosorbide nitrate | |
JP2001039864A (en) | Felbinac-containing plaster | |
JP3525272B2 (en) | Skin sticking sheet | |
JPS62230715A (en) | Novel plaster preparation | |
JPH05331064A (en) | Anti-inflammatory analgesic plaster | |
JPH0517346A (en) | Agent for medical application | |
JP2632838B2 (en) | External patch | |
JP2007031322A (en) | Plaster | |
JPH01297069A (en) | Tacky adhesive agent composition | |
JPH06172164A (en) | Plaster |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080105 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090105 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |